Cell News and Research

RSS

Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer

Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).

20 Jul 2010

NanoViricides presents study results of nanoviricides anti-Ebola agents

NanoViricides, Inc. reports that the results of the evaluation of several of its nanoviricides anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."

20 Jul 2010

Researchers reveal findings on restricted lineage of iPS cells

Adult cells that have been reprogrammed into induced pluripotent stem cells (iPS cells) do not completely let go of their past, perhaps limiting their ability to function as a less controversial alternative to embryonic stem cells for basic research and cell replacement therapies, according to researchers at Children's Hospital Boston, John Hopkins University and their colleagues

20 Jul 2010

Scientists develop new way to increase effectiveness of antiviral drugs

Scientists have developed a new way to target viruses which could increase the effectiveness of antiviral drugs.Instead of attacking the virus itself, the method developed at the University of Edinburgh alters the conditions which viruses need to survive and multiply.

20 Jul 2010

New approach to understand different cancer subtypes

An international team led by St. Jude Children's Research Hospital scientists finds unique combinations of cells and mutations lie at the heart of cancer subgroup revealed for the first time in a pediatric brain tumor

20 Jul 2010

Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial

Argos Therapeutics today announced that, in an interim analysis of a Phase 2 trial, its Arcelis immunotherapy targeted at HIV, AGS-004, demonstrated a significant reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment interruption (ARTI) when compared to pre-ART viral loads.

20 Jul 2010

Rottapharm Madaus, Selvita sign drug discovery services contract

Rottapharm Madaus and Selvita announced today signature of a services contract for delivery of drug discovery services. The aim of this project is to deliver to Rottapharm Madaus a set of designed and synthesized compounds, including their optimized synthesis route, which will have a therapeutic potential in an indicated area.

20 Jul 2010

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.

20 Jul 2010

Cellectis bioresearch introduces new technology to develop cell-based assays for HTS studies

Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis, today announced the publication of a scientific study describing a novel method, based on meganuclease-driven targeted integration, for the generation of stable cell lines compatible with high throughput screening (HTS).The study demonstrated Cellectis bioresearch's technology to be faster, more reliable and efficient in deriving cell-based assays for HTS studies than classical methods.

20 Jul 2010

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

"Treating HIV patients with cocktails of AIDS drugs helps to stop them spreading the infection further and more than halved the number of new HIV diagnoses in a study in Canada, scientists said on Sunday," Reuters reports.

20 Jul 2010

Rice University bioengineers win $1.7M NIH grant for cartilage-regeneration research

Bioengineers from Rice University's BioScience Research Collaborative have won a $1.7 million grant from the National Institutes of Health to develop an injectable mix of polymers and adult stem cells that can spur the growth of new cartilage in injured knees and other joints.

20 Jul 2010

Thymosin beta 4 improves neurological functional outcome after embolic stroke: Researchers

RegeneRx Biopharmaceuticals, Inc. today announced a research team from the Henry Ford Hospital in Detroit, MI, reported that Thymosin beta 4, administered to rats after embolic stroke, improved neurological functional outcome compared to control animals.

20 Jul 2010

ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma

ZIOPHARM Oncology, Inc. today announced the initiation of the pivotal Phase III clinical trial for palifosfamide in patients with front-line metastatic soft tissue sarcoma. The study, called PICASSO 3, is an international, randomized, double-blinded, placebo-controlled trial designed to enroll approximately 424 patients with metastatic soft tissue sarcoma who have never been treated with chemotherapy for metastatic disease.

20 Jul 2010

T-SPOT.TB test predicts TB infected persons better than TST: Study

The authors of a recent study published in the American Journal of Respiratory and Critical Care Medicine concluded that the T-SPOT.TB test is better than the tuberculin skin test at predicting which patients will develop active TB.

20 Jul 2010

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

Researchers discover new gene regulation, DNA behavior of breast cancer cells

Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.

20 Jul 2010

Researchers discover genetic explanation for non-diabetic kidney disease in African-Americans

Kidney disease is a growing public health problem, with approximately half a million individuals in the United States requiring dialysis treatments to replace the function of their failed kidneys. The problem is particularly acute among African-Americans, whose rates of kidney disease are four times higher than those of European Americans.

20 Jul 2010

Researchers identify a mechanism that explains different phases of CML progression

Researchers at Duke University Medical Center have identified a mechanism that could explain how patients move into the worst phase of chronic myelogenous leukemia.

20 Jul 2010

Bionas launches new Bionas adcon reader for impedance-based, cellular analysis

Bionas GmbH announces the launch of its new Bionas® adcon reader for impedance-based, cellular analysis. The Bionas adcon reader technology is based on real-time monitoring of cellular impedance, thus giving real-time data about cell adhesion, membrane integrity, cellular morphology and cell proliferation for applications in toxicology, oncology, receptor signaling as well as the quality management of cells.

19 Jul 2010

Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer

Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.

19 Jul 2010

Cell News and Research

Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer

NanoViricides presents study results of nanoviricides anti-Ebola agents

Researchers reveal findings on restricted lineage of iPS cells

Scientists develop new way to increase effectiveness of antiviral drugs

New approach to understand different cancer subtypes

Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial

Rottapharm Madaus, Selvita sign drug discovery services contract

CytRx updates on progress in clinical development of bafetinib in three oncology indications

Cellectis bioresearch introduces new technology to develop cell-based assays for HTS studies

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

Rice University bioengineers win $1.7M NIH grant for cartilage-regeneration research

Thymosin beta 4 improves neurological functional outcome after embolic stroke: Researchers

ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma

T-SPOT.TB test predicts TB infected persons better than TST: Study

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Researchers discover new gene regulation, DNA behavior of breast cancer cells

Researchers discover genetic explanation for non-diabetic kidney disease in African-Americans

Researchers identify a mechanism that explains different phases of CML progression

Bionas launches new Bionas adcon reader for impedance-based, cellular analysis

Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News